AGIO (Agios Pharmaceuticals) YoY EBITDA Growth : 2.42% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Agios Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 2.42%.

Agios Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2024 was $-1.74.

Agios Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Agios Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals YoY EBITDA Growth Chart

Agios Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

12.96

7.98

-29.19

-13.72

0.42

Agios Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															-9.48	-5.81	-0.12	-11.01	2.42

Agios Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Agios Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-6.916	-	-6.945)	/	\| -6.945 \|
=	0.42 %

Agios Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2024 )
=	(EBITDA per Share (Q: Sep. 2024 )	-	EBITDA per Share (Q: Sep. 2023 ))	/	\| EBITDA per Share (Q: Sep. 2023 )) \|
=	(-1.736	-	-1.779)	/	\| -1.779 \|
=	2.42 %

Agios Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

AGIO:Mexico 0HB0:UK 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Executives

Rahul D. Ballal	director	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Washburn Theodore James Jr.	officer: Principal Accounting Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns	officer: Chief Legal Officer	C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Brian Goff	director, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens	officer: Chief Medical Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Schenkein	director, 10 percent owner, officer: Chief Executive Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Tsveta Milanova	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen	director	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Richa Poddar	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson	officer: Principal Accounting Officer	88 SIDNEY STREET, CAMBRIDGE MA 02139